Dutch artificial intelligence (AI) software developer ScreenPoint Medical has appointed Mark Koeniguer as its new CEO.
Koeniguer comes to ScreenPoint with more than 25 years of healthcare industry experience, including entrepreneurial ventures as well as various executive positions at GE Healthcare. He has been hired to lead ScreenPoint's next growth phase and accelerate its international expansion, according to the vendor.
Koeniguer replaces ScreenPoint co-founder Nico Karssemeijer, PhD, who will remain on as chief scientific officer. In his new role, Karssemeijer will focus on studies with clinical partners and AI research to support product development, ScreenPoint said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
